top of page

Tissue-Agnostic MRD Assay to Predict Recurrence in Head & Neck Cancer

Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, presented initial results demonstrating the ability of its MRD assay to predict recurrence in head & neck cancer, at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024. FOSTER CITY, Calif., April 8, 2024 /PRNewswire/ — Adela, Inc., an innovator in blood testing for minimal residual disease monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, presented initial results demonstrating the ability of its MRD assay to predict recurrence in head & neck cancer, at the American Association for Cancer Research (AACR) Annual Meeting from April 5-10, 2024. „In patients with head & neck cancer, determining the most appropriate course of action following curative intent treatment can be challenging due to the need to balance the potential side effects of treatment with the ramifications of recurrence. Furthermore, detection of recurrence is complicated by inaccuracies of medical imaging and a lack of standardized surveillance procedures“, said Scott Bratman MD, PhD, Chief Innovation Officer, Adela and Radiation Oncologist and Clinician-Scientist at Princess Margaret Cancer Centre, University Health Network. „We are highly encouraged by these initial results and the potential for a novel approach to improve care of patients with head & neck cancer.“ The ability of Adela’s assay to quantify cfDNA cancer signal and predict recurrence was evaluated in individuals diagnosed with stage I-IVB human papillomavirus (HPV)-negative and HPV-positive head and neck cancer treated at Princess Margaret Cancer Centre, University Health Network. This training analysis included 249 plasma samples collected from 75 patients (a subset of the full cohort of >1,100 plasma samples from >300 individuals). Blood draws occurred before and after curative intent treatment, and in a subset of patients, at 12 and 24 months post-curative intent treatment. Adela’s MRD assay demonstrated the ability to identify patients more likely to recur than not, based on the blood draw following curative intent treatment (i.e., landmark), and also at the longitudinal timepoints. Significant differences in recurrence-free survival (RFS) were observed, with a hazard ratio (HR) of 10.97 (P<0.001) at the landmark timepoint, and an HR of 22.83 (P<0.001) longitudinally, when patients were stratified by MRD positivity.

Aktuelle Beiträge

Alle ansehen

Comments


bottom of page